Attenuation of HbA1 creduction was not edin both study arms at 104 weeks;however,the gradual increase in HbA1c over time was less profound with dapagliflozin than with glipizide. At week 208, dapagliflozin was associated with a reduced HbA1c concentration compared with glipizide (−0.10 vs 0.20%, respectively). This emphasized the between-group differences in HbA1c reduction during the extension periods [week 104,
−0.18% (95% CI −0.33, −0.03); week 208, −0.30% (95% CI −0.51, −0.09), Figure 1A]. Subgroup analyses showed similar patterns in HbA1c reduction, with greater effects as baseline HbA1c levels increased.To account for patient attri tionin this long-term trial, longitudinal repeated measures analyses that included data after rescue were conducted and showed similar patterns of HbA1 creduction.
Attenuation of HbA1 creduction was not edin both study arms at 104 weeks;however,the gradual increase in HbA1c over time was less profound with dapagliflozin than with glipizide. At week 208, dapagliflozin was associated with a reduced HbA1c concentration compared with glipizide (−0.10 vs 0.20%, respectively). This emphasized the between-group differences in HbA1c reduction during the extension periods [week 104,−0.18% (95% CI −0.33, −0.03); week 208, −0.30% (95% CI −0.51, −0.09), Figure 1A]. Subgroup analyses showed similar patterns in HbA1c reduction, with greater effects as baseline HbA1c levels increased.To account for patient attri tionin this long-term trial, longitudinal repeated measures analyses that included data after rescue were conducted and showed similar patterns of HbA1 creduction.
การแปล กรุณารอสักครู่..
